SLC30A2

Across TCGA pan-cancer cohorts, SLC30A2 mass-spec protein is linked to patient survival in 2 of 34 cancer types, making it a survival-associated SLC30A2 data layer compared with 23 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SLC30A2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated SLC30A2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC show a favorable association.

PDAC and CCRCC are the cancer types where SLC30A2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	All	0.362	0.679	.004	15	view →
CCRCC	OS	Quartile	All	0.945	0.669	.028	4	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

SLC30A2–PDAC (OS)

Open the PDAC breakdown →